Oct 25th, 2023

Late-Breaking Science and Featured Science for Sunday

Today's Late-Breaking Science sessions focus on atrial fibrillation and novel approaches to lipid-lowering therapies.

standing ovation by the audience at a Main Event

LBS.05: Shocking Decisions in AFib Care

8-9:15 a.m. | Main Event I

• Efficacy and Safety of Dual Direct Current Cardioversion Versus Single Direct Current Cardioversion as an Initial Treatment Strategy in Obese Patients With Atrial Fibrillation

• Abelacimab, a Novel Factor XI/XIa Inhibitor, Versus Rivaroxaban in Patients With Atrial Fibrillation: Primary Results of the AZALEATIMI 71 Randomized Trial (AZALEA-TIMI 71)

• Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours: The NOAH-AFNET 6 Trial (NOAH-AFNET 6)

• Apixaban for the Prevention of Stroke in Patients With Subclinical Atrial Fibrillation (ARTESIA)

LBS.06: Future of Lipid-Lowering Therapy — Novel Mechanisms and Approaches

3:30-4:45 p.m. | Main Event I

• Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

• Recaticimab Add-On Therapy in Patients With Non-Familial Hypercholesterolaemia and Mixed Hyperlipidemia (REMAIN-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (REMAIN-2)

• Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a)

• Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol—Interim Results of the Phase 1b heart-1 Trial (VERVE-101)